Disc Medicine, Inc. (IRON)

Disc Medicine’s second fiscal quarter of 2026 showed an EPS result that topped consensus, based on preliminary figures reported July 30, 2026, with EPS of -$1.54 topping the -$1.71 estimate by $0.17 as the company posted a wider loss year over year. Net income was a loss of about $59.5 million, down 7.8% from a loss of roughly $55.2 million a year ago, while operating income was a loss of about $65.1 million. Cash flow also remained negative, with negative operating cash flow of roughly $44.2 million in the quarter. Disc Medicine, a clinical-stage biotech focused on therapies for red blood cell biology, continues to run primarily through R&D activity rather than commercial revenue contribution. For the next period, consensus calls for EPS of -$1.65 on revenue of $1.9 million.